Health In Focus
  • Canaglifozin found to significantly lower the risk for heart failure in type 2 diabetes patients.
  • Type 2 diabetes patients were assessed for the risk of heart failure, particularly in patients with established or high risk for cardiovascular disease.
  • Canagliflozin compared with other non-SGLT2 inhibitors for its cardiovascular adverse effects.

Canagliflozin is an anti-diabetes drug belongs to the gliflozin class or sodium-glucose transport subtype two inhibitors. Canagliflozin is administered either as a monotherapy or with metformin, sulfonylurea drugs, pioglitazone or insulin to achieve adequate glycemic control while treating diabetes patients.

Canagliflozin Vs. Other Non-SGLT2 Inhibitor Drugs

Canagliflozin, a sodium-glucose cotransporter-2 inhibitor works by blocking the reabsorption of glucose in the proximal convoluted tubule found to lower the risk of cardiovascular events, particularly in patients who have a strong history of heart disease. The research team conducted a population-based retrospective cohort study for comparing the cardiovascular outcomes of canagliflozin and other anti-diabetes drugs.
Canagliflozin Associated Cardiovascular Outcomes in Type 2 Diabetes

Non-SGLT2 inhibitor drugs involved in the study were dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide receptor (GLP-1) agonists or sulfonylurea drugs which were compared with canagliflozin during the study. The treatment with canagliflozin was associated with a lower risk of heart failure admission in a hospital, while compared with the other three anti-diabetic drugs. Although the risk of heart failure was reported to be low in canagliflozin treatment, the risk for stroke or myocardial infarction were found to be similar with canagliflozin as well as with other non-gliflozin or non-SGLT2 inhibitor drugs.

When should you not take Canagliflozin?

What Precautions Need to be Taken while Taking Canagliflozin?

  • Monitor kidney functions regularly as canagliflozin affects the organ.
  • Ketoacidosis can be fatal, and patients should be monitored for too much acid in urine or blood, and in some cases, severe urinary tract infections can occur.
  • Canagliflozin can increase the chance of weakening the bones and patients should be advised to consult the physician if a sudden pain in the joints occurs.
  • To get the maximum benefit of canagliflozin, do not miss the dose.
  • Sudden decrease in blood sugar can happen especially when canagliflozin taken with other anti-diabetic drugs and patients must be educated to recognize the hypoglycemia signs
  • Blood sugar should be monitored regularly and do not increase or decrease the dose of canagliflozin without doctor's approval.

What are the side effects of Canagliflozin?

  • Low blood sugar
  • Urinary tract infections
  • Genital mycotic infections
  • Diabetic ketoacidosis
  • Increased urinary frequency
  • Low blood pressure
  • Dehydration
  • Constipation
  • Risk of bone fracture
  • Pancreatitis
References :
  1. Cardiovascular Outcomes with Canagliflozin vs. Non-SGLT2 Inhibitor Antidiabetes Drugs - (
  2. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study - (
  3. Canagliflozin Wikipedia - (
  4. Canagliflozin Drug Information - (
  5. Canagliflozin Drug - (
Source: Medindia

Most Popular on Medindia